Lymphoma

Last updated: 01 November 2019

You can legally access new medicines, even if they are not approved in your country.

Learn how

Brentuximab vedotin (Adcetris) has now been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) who have had at least 1 prior systemic therapy.